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Advanced Age is not a Contraindication for
Primary Infarct Angioplasty in Patients with
Cardiogenic Shock
The degree of reperfusion achieved following intravenous (IV) thrombolysis
is an important factor in patient prognosis. and rapid non-invasive identifica-
tion of this in the management of acute myocardial infarction is essential.
Recently. IV sonicated dextrose albumin (SDA) perfused with a gas of low
blood solubility and diffusivity (perfluoropropane (PF)) has been capable of
producing myocardial contrast following IV injection which correlates closely
with coronary blood flow (CBF). We hypothesized that this agent could de-
tect the amount of CBF following coronary reperfusion. Accordingly. we gave
a standard dose (0.06 mllkg) of IV PF-enhanced SDA (PESDA) in seven dogs
at baseline. during acute ischemia produced by a 100% left circumflex (LCX)
ligature, and during reperfusion (REP) but with quantitative angiographic (au-
tomated border detection) evidence of a residual stenosis (RS) varying from
19 to 90% in diameter. The background-subtracted peak myocardial videoin-
tensity (PMVI) produced by IV PESDA was measured in the LCX and left
anterior descending (LAD) perfusion beds. and correlated with actual flow
(CBF) using a Doppler flow cuff over the LCX and LAD. as well as RS sever-
ity by quantitative angiography (OA). Wall thickening (WT) responses were
also measured as the difference in LCX perfusion bed end-diastolic and end-
systolic wall thickness. The presence of infarction was documented with
triphenyl tetrazolium chloride (TIC) staining.
The range of Doppler flows in the LCX following reperfusion was 8-50
mllmin. There was a strong correlation (r = 0.85. p < 0.001) between resid-
ual LCX CBF after REP with a RS and PMVI in the LCX perfusion bed. Failure
of PMVI to return to baseline PMVI following REP was seen only in dogs
who had a greater than 80% RS. The correlation between PMVI and LCX
flow remained good when the RS was removed except where there was
TIC evidence of infarction. There was also a correlation between RS sever-
ity by QA and LCX PMVI (r = 0.63; P = 0.002). In contrast. WT correlated
poorly with LCX flow following REP (r = 0.44). These data indicate that PMVI
following intravenous PESDA can detect residual coronary blood flow ab-
normalities following REP of a totally occluded coronary artery. This agent.
therefore. could potentially be used in humans to non-invasively determine
the degree of coronary blood flow achieved following reperfusion therapy in
acute myocardial infarction.
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Patients with cardiogenic shock during acute myocardial infarction have high
mortality. It has been suggested that survival rates approach zero in those
patients over age 75. and therefore intervention is contraindicated. We re-
port a retrospective review of 97 patients presenting with cardiogenic shock
during acute infarction with analysis based on patient age. Acute infarction
was defined by standard ECG criteria. Cardiogenic shock was defined by sys-
tolic pressure <80 mmHg with evidence of systemic hypoperfusion in the
presence of adequate filling pressures.
The groups were similar in respect to infarct location. number of dis-
eased arteries. prior CABG, and diabetes; there was a greater percentage
of women in the elderly group vs. the younger group (61.5% vs. 31.0%. p =
0.01). Results of therapy are as follows:
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poperfusion with intravenously (IV) injected contrast remains difficult be-
cause of the lack of an ideal agent. and problems in resolution of transtho-
racic 2DE images. In this study, we explored the potential of 2 new ap-
proaches: 1) a new IV contrast agent, FS069 (MBI) that can cross the pul-
monary circulation and 2) Intracardiac echocardiography (ICE) that can de-
pict LV myocardium crisply. In 5 anesthetized dogs. ICE was performed us-
ing a 6 Fr. 12.5 MHz catheter within the LV Once short-axis views were ob-
tained. a small dose (0.3 mg) of FS069 was injected into the femoral vein
at baseline. following occlusion of the LAD. PDA, and OM coronary arteries,
and after reperfusion. Continuous ICE monitoring was performed. Perfusion
defects. quantified and expressed as % of LV, were correlated with the ex-
tent of regional wall motion abnormalities (WMA) measured in ICE images
without contrast. Results: After IV injection, the RV cavity was opacified, fol-
lowed by the LV cavity. All endocardial borders were well defined. Contrast
enhancement was noted within the myocardium within 5 beats of LV cavity
opacification. During 18 episodes of ischemia we produced. opacification of
the LV cavity facilitated identification of WMA in all. Perfusion defects corre-
sponding to WMAs were observed in all cases where WMAs were present;
however 2 episodes of ischemia were not accompanied by either contrast
defects or WMA. Defects were visible long enough for ICE to image the LV
at multiple levels. Following reperfusion and re-injection of contrast. no de-
fects were noted. The perfusion defects ranged from 13-62% (mean 37.6
± 14.8) of the total LV; the extent of WMA was 14-66% (mean 39.0 ± 15.2)
of the LV circumference. Defect size (x) correlated well with extent of WMA
Iy), with y = 0.98x + 2.1. r = 0.95. P < 0.001. Conclusion: (1) IV injection
of FS069 is sensitive and strong enough to demonstrate myocardial perfu-
sion and ischemia that can be quantified by ICE; (2) Contrast changes persist
long enough to image all levels of the LV by ICE; (3) Catheter-based imaging,
when refined. could be useful for monitoring ischemia and perfusion status.
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Detection of myocardial opacification after intravenous injection of contrast
is of great diagnostic value. To achieve this goal. we applied harmonic imag-
ing to myocardial contrast echocardiography. Contrast agents emit strong
harmonics at double the frequency of transmitted ultrasound. while the tis-
sue does not. Thus. harmonic imaging improves the tissue-agent contrast.
We used a prototype phased-array harmonic echocardiographic system with
a sector probe that transmits ultrasound at 2.5 MHz and receives at 5 MHz
(Toshiba Corp.). SHU-508 (Schering). a galactose-based contrast agent, was
injected through femoral vein (0.13-0.24 mllkg; 400 mg/ml) in 5 anesthetized
open chest dogs. Images were recorded on videotapes and subsequently
analyzed with a Quadra 840AV (Apple) based microcomputer system. Time-
intensity plots were generated in the end-diastolic images by setting the re-
gion of interest to the anterior LV wall. In 3 dogs. shortly after the opacifi-
cation in LV lumen, the intensity in the myocardium increased and gradually
declined to the basal level as shown in the figure. No significant hemody-
namic alterations were noted with these doses of SHU-50S. Thus, success-
ful myocardial opacification can be achieved during harmonic imaging after
intravenous injection of contrast. Harmonic contrast echocardiography is a
feasible. promising technique to detect myocardial perfusion.
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Subgroup Procedural success In hospital mortality
Age < 70(n = 71)
Age", 70(n ~ 26)
80.3%,
84.6%.
P = 0.84
42.3%.
53.8%.
P = 0.43
The occurrence of urgent CABG and stroke was similar between groups.
Mortality remained comparable between age groups regardless of proce-
dural success or failure. Using multivariate analysis, infarct location (anterior
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Conclusions: 1) ICP use is steadily increasing in MI pts ineligible for TTX
in Israel; 2) increased ICP rates are associated with decrease of early death
among M I patients ineligible for TTX.
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In the reperfusion era thrombolytic trials reported a "smoker's paradox" in
which a favorable clinical outcome was noted in smokers. This was thought
to be due in part to the hypercoagulable state with smoking, resulting in a
more thrombotic coronary occlusion which responds well to thrombolysis.
To determine whether the type of reperfusion strategy affects outcome in
smokers vs. nonsmokers, we evaluated 395 patients (pts) who were random-
ized to tPA vs. primary PTCA in the PAMI study of whom 168 were smokers
(SM) and 128 never smoked INS). The combined in-hospital outcome includ-
ing death, recurrent MI or recurrent ischemia was similar in SM and NS (p
= 0.12) despite univariate analysis revealing that SM were younger (65 vs.
55 yrs, p < 0.001) and less likely to be female (20 vs. 41%, P < 0.001) com-
pared with NS. Stratifying the data according to reperfusion modality, smok-
ers treated with tPA did significantly better than NS (p = 0.041; a difference
that did not exist in the PTCA group (SM vs NS, p = 0.69). Multivariate anal-
ysis revealed that NS treated with PTCA had less recurrent ischemia (11 vs.
33%, p ~ 0.004) and combined mortality or recurrent MI (7 vs 18%, P =
0.05) compared with those treated with tPA. At 6 months, NS treated with
PTCA vs. tPA continued to have fewer deaths or recurrent MI. (11 vs. 24%,
P = 0.07). Conversely, treatment strategy in SM did not significantly affect
hospital outcomes; recurrent ischemia (12 vs. 23%, P = 0.07) and mortality
combined with recurrent MI (6 vs. 8%, P = 0.55) in PTCA and tPA groups. The
statistical significance of these associations is maintained when controlling
for age and gender.
Conclusion: Nonsmokers presenting with acute MI have a significantly bet-
ter outcome after treatment with primary angioplasty. Even when controlling
for age and gender the reperfusion strategy affects outcome in NS, a differ-
ence not seen in SM. These data add further support to the hypothesis that
nonsmokers have a more atherosclerotic occlusion which may explain why
they benefit from primary angioplasty more than thrombolysis.
ST elevation MI (n = 94):
Age 2: 75 yrs (n ~ 78):
Onset ~ 12 hrs (n = 1631:
Chronic angina (n = 114):
Chronic CHF In = 51):
Prior MI (n = 108):
Hospital death (n ~ 28):
The most common reason for not treating with n was absence of criteria
for ST elevation MI in 179/222 pts 181 %). Of 35/222 (16%) who presented
between 4-12 hrs, age or duration of symptoms was the sole contraindica-
tion to n in only 8 (4%). Other less common major contra indications to TT
included prolonged chest massage, recent surgery, active internal bleeding,
and hemodynamic instability. Conclusions: 1) Most pts did not receive n.
2) Even with expanded treatment criteria, few additional pts become can-
didates for n. 3) Future research should focus on the majority of the MI
population which fails to meet ECG or other n criteria.
Thrombolytic therapy In) clearly saves lives in acute myocardial infarction
IMI). but the major limitation to its widespread use has been the large propor-
tion of M I pts considered ineligible for n. In recent overviews of the large
randomized n trials, net benefit is consistently seen with: 1) ST elevation
Mlldiagnostic ST elevations in any anatomic location) or left bundle branch
block on presenting ECG; 2) any age; and 3) onset of symptoms < 12 hrs.
To describe correlates of n utilization and to determine the potential impact
of recently expanded n criteria on the number of untreated pts, we studied
292 pts with acute MI who were admitted via the Emergency Department
between June 1991 and December 1992 into a large university teaching hos-
pital.
Results: 222 (76%) did not receive n. Univariate correlates of n utilization:
Eligibility for Thrombolytic Therapy is Limited
Even with Expanded Criteria
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In order to determine whether expanding use of thrombolytic therapy (n)
has influenced overall acute myocardial infarction (AMI) outcome, we eva 1-
Expanding Indications for Thrombolytic Therapy
Improves Acute Myocardial Infarction Outcome
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The Use of Invasive Coronary Procedures Have
Increased and Prognosis Improved in Patients
Ineligible for Thrombolysis in Israel
Solomon Behar, Shmuel Gottlieb, Gavriel Barbash, Thrombolytic Israeli Survey
Group. Neufeld Cardiac Research Institute, Tel-Aviv University. Israel
Characteristics (%) 1990 (n = 267) 1992 In ~ 546) 1992 In ~ 567)
Men 68 75 69
Age (mean + SO) 65±11yrs 65± 12yrs 65± 12yrs
>75 yrs 21 25 22
First MI 66 63 60
ICP(%)
Coronaro-angiography 15 18 27
PTCA <1 6 11
CABG <1 2 5
Mortality (%) 13 10 8
17 days)
We also instituted this AMI team approach in three area small town rural
hospitals to see if this approach would be beneficial in this setting. Similar
reductions in time to treatment were observed.
Conclusion: 1) AMI team approach effectively lowers time to treatment
in large medical center hospitals and in small town rural hospitals; 2) wide-
spread use of this concept could significant lower mortality from ST segment
elevation AMI in the United States.
vs. other) was the only variable predicting mortality. Age was not a predictive
factor using univariate analysis; using multivariate analysis there was a trend
towards increasing mortality with age, which did not reach statistical signif-
icance. We conclude advanced age is not invariably associated with a fatal
outcome in acute infarction patients with cardiogenic shock and encourage
consideration of infarct angioplasty in patients presenting with shock regard-
less of patient age.
Stephen L. Kopecky, Martha J. Siska, Jean A. Jurek, Stephen F. Gudgell, Thomas
D. Meloy, Deborah R. Fischer, Guy S. Reeder. Mayo Clinic, Rochester, MN
In the United States, the average time between a patient's arrival in the emer-
gency room (ER) and the administration of thrombolytic therapy for ST ele-
vation and acute myocardial infarction (AMI) is over one hour. If the time to
treatment (Rx) after arrival in the ER could be reduced by 30 minutes, it has
been estimated that at least 5,000 lives could be saved annually in the United
States. In our institution, the average time to Rx after arrival in the ER for ST
elevation AMI from June 1991 to June 1993 was 71 ± 32 minutes Imedian
64 minutes). We then developed an "AMI team" approach which included
ER physicians, ER nurses, ECG technicians, and pharmacists. The diagnos-
tic approach of the AMI team was based on two pocket cards that contained
information on the following: 1) indicationslcontraindications of thrombolytic
treatment in AMI; 2) thrombolytic treatment drug selection guidelines ItPA
versus SK); 31 ancillary therapy drugs and dosages; and 4) ancillary therapy
indications/contraindications. Treatment by the AMI team centered around
an AMI kit-a tackle box that contained both thrombolytic drugs, all necessary
ancillary treatments (ASA. heparin, beta blockers, nitrates, MS, and magne-
sium) and IVtubing plus drug compatibility charts The time to Rx before and
after institution of the AMI team was as follows:
Patients (pts) with acute myocardial infarction (AMII ineligible for throm-
bolytic therapy (TTX) are at increased risk. Invasive coronary procedures (ICP)
have been recommended for these pts. In 3 surveys performed in the CCU's
of Israel during 1990, '92 and '94 the use of nx was 35, 46 and 43% respec-
tively. The characteristics and management of excluded pts from TTX in the
respective surveys were as follows:
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